STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer

Trastuzumab‐emtansine (T‐DM1) is an antibody‐drug conjugate that has been approved for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer. Despite the remarkable efficacy of T‐DM1 in many patients, resistance to this therapeutic has emerged as a signif...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Wang, Quanren, Gao, Mingzhao, Fu, Li, Li, Yun, Quan, Haitian, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172075/
https://www.ncbi.nlm.nih.gov/pubmed/30076657
http://dx.doi.org/10.1111/cas.13761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172075/
https://www.ncbi.nlm.nih.gov/pubmed/30076657
http://dx.doi.org/10.1111/cas.13761

Ejemplares similares